These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 27082551)

  • 21. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial.
    Ruggenenti P; Perna A; Ganeva M; Ene-Iordache B; Remuzzi G;
    J Am Soc Nephrol; 2006 Dec; 17(12):3472-81. PubMed ID: 17082240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group.
    Laffel LM; McGill JB; Gans DJ
    Am J Med; 1995 Nov; 99(5):497-504. PubMed ID: 7485207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).
    Marre M; Lievre M; Chatellier G; Mann JF; Passa P; Ménard J;
    BMJ; 2004 Feb; 328(7438):495. PubMed ID: 14960504
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased mortality in patients with diabetes associated with olmesartan for the prevention/delay of microalbuminuria onset: a matter of concern?
    Consuegra-Sánchez L; Sanchis J; Núñez J; Cascón JD; Villegas M; Picó F
    Rev Esp Cardiol (Engl Ed); 2012 Apr; 65(4):378-80. PubMed ID: 21840109
    [No Abstract]   [Full Text] [Related]  

  • 25. Preemptive olmesartan for the delay or prevention of microalbuminuria in diabetes.
    Ingelfinger JR
    N Engl J Med; 2011 Mar; 364(10):970-1. PubMed ID: 21388316
    [No Abstract]   [Full Text] [Related]  

  • 26. Update on the ROADMAP clinical trial report: olmesartan for the prevention or delay of microalbuminuria development in type 2 diabetes.
    Chatzikyrkou C; Menne J
    Expert Rev Cardiovasc Ther; 2012 Sep; 10(9):1087-92. PubMed ID: 23098143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preventing microalbuminuria in type 2 diabetes.
    Ruggenenti P; Fassi A; Ilieva AP; Bruno S; Iliev IP; Brusegan V; Rubis N; Gherardi G; Arnoldi F; Ganeva M; Ene-Iordache B; Gaspari F; Perna A; Bossi A; Trevisan R; Dodesini AR; Remuzzi G;
    N Engl J Med; 2004 Nov; 351(19):1941-51. PubMed ID: 15516697
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olmesartan, microalbuminuria, and type 2 diabetes.
    Fioretto P; Mauer M
    N Engl J Med; 2011 Jun; 364(23):2260-1; author reply 2262-3. PubMed ID: 21651400
    [No Abstract]   [Full Text] [Related]  

  • 29. Effect of low-dose perindopril/indapamide on albuminuria in diabetes: preterax in albuminuria regression: PREMIER.
    Mogensen CE; Viberti G; Halimi S; Ritz E; Ruilope L; Jermendy G; Widimsky J; Sareli P; Taton J; Rull J; Erdogan G; De Leeuw PW; Ribeiro A; Sanchez R; Mechmeche R; Nolan J; Sirotiakova J; Hamani A; Scheen A; Hess B; Luger A; Thomas SM;
    Hypertension; 2003 May; 41(5):1063-71. PubMed ID: 12654706
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Olmesartan, microalbuminuria, and type 2 diabetes.
    Yudkin JS; Lehman R
    N Engl J Med; 2011 Jun; 364(23):2260; author reply 2262-3. PubMed ID: 21651401
    [No Abstract]   [Full Text] [Related]  

  • 31. Impact of renin-angiotensin system inhibition on microalbuminuria in type 2 diabetes: a post hoc analysis of the Shiga Microalbuminuria Reduction Trial (SMART).
    ; Uzu T; Sawaguchi M; Maegawa H; Kashiwagi A
    Hypertens Res; 2008 Jun; 31(6):1171-6. PubMed ID: 18716365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Olmesartan, microalbuminuria, and type 2 diabetes.
    Lammert A; Krämer BK; Krüger B
    N Engl J Med; 2011 Jun; 364(23):2261; author reply 2262-3. PubMed ID: 21651399
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential effects of beta-blockers on albuminuria in patients with type 2 diabetes.
    Bakris GL; Fonseca V; Katholi RE; McGill JB; Messerli F; Phillips RA; Raskin P; Wright JT; Waterhouse B; Lukas MA; Anderson KM; Bell DS;
    Hypertension; 2005 Dec; 46(6):1309-15. PubMed ID: 16286578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. The EUCLID Study Group.
    Lancet; 1997 Jun; 349(9068):1787-92. PubMed ID: 9269212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative study of the efficacy of olmesartan/amlodipine vs. perindopril/amlodipine in peripheral blood pressure after missed dose in type 2 diabetes.
    Redon J; Pichler G;
    J Hypertens; 2016 Feb; 34(2):359-67. PubMed ID: 26867060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria.
    Kohlmann O; Roca-Cusachs A; Laurent S; Schmieder RE; Wenzel RR; Fogari R
    Adv Ther; 2009 Mar; 26(3):313-24. PubMed ID: 19330493
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.
    White WB; Weber MA; Sica D; Bakris GL; Perez A; Cao C; Kupfer S
    Hypertension; 2011 Mar; 57(3):413-20. PubMed ID: 21282560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.
    Ravid M; Savin H; Jutrin I; Bental T; Katz B; Lishner M
    Ann Intern Med; 1993 Apr; 118(8):577-81. PubMed ID: 8452322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan.
    Smith DH; Dubiel R; Jones M
    Am J Cardiovasc Drugs; 2005; 5(1):41-50. PubMed ID: 15631537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.